How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The latest research update on BioXcel Therapeutics cuts the price target from US$10 to US$6, alongside a modest trim in the fair value estimate from $15.25 to $14.25. Bulls see this move as a recalibration that still leaves room for upside, while bears point to the lower target as a signal that equity dilution and funding needs are front and center. As you read on, you will see how these shifting views shape the evolving narrative around the stock and what to watch next. Stay updated as the Fair Value for BioXcel Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on BioXcel Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways H.C. Wainwright maintains a Buy rating on BioXcel Therapeutics, signaling that, in its view, the latest price target change does not alter the core long term thesis. The firm's updated US$6 price target still implies room above recent trading levels for inve
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.GlobeNewswire
- BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
- BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingGlobeNewswire
- BioXcel Therapeutics (BTAI) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
BTAI
Earnings
- 11/12/25 - Miss
BTAI
Sec Filings
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- BTAI's page on the SEC website